epirubicin + filgrastim

Epirubicin + filgrastim is a combination regimen used primarily in oncology to enable higher-dose or dose-dense chemotherapy by mitigating the risk of severe neutropenia. Epirubicin is an anthracycline antineoplastic agent that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cancer cells. Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursors, reducing the incidence, severity, and duration of chemotherapy-induced neutropenia. This combination allows for intensified or more frequent administration of epirubicin-containing regimens by supporting faster recovery of white blood cell counts[1][2][3][6].